This study was performed to investigate the anti-obesity and anti-lipidemic ability of linalool (LL) in ApoE deficient mice fed a high-fat diet (HFD). Mice were divided into four experimental groups of eight each. Mice in the control group received a basic diet and oral repeated dose of the vehicle only for 12 weeks; mice in the HFD group received a HFD and oral repeated dose of the vehicle only for 12 weeks; and the HFD&LL25 and HFD&LL50 groups received a HFD and oral repeated dose of LL 25 and 50 mg/kg/day for 12 weeks, respectively. Mice in the HFD group showed a significant increase in body weight, spleen weight, and adipose tissue weight, compared with the control group. An increase in the serum levels of aspartate aminotransferase and alanine aminotransferase activities, total cholesterol (T-CHO), triglyceride (TG), and low density lipoprotein cholesterol was also observed in the HFD group. Histopathological examinations showed severe liver injuries, characterized by extensive fatty changes and hepatocyte degeneration/necrosis. On the contrary, oral administration with LL resulted in significantly improved HFD-induced obesity and hyperlipidemia, indicated by a decrease in adipose tissue weight, T-CHO, TG, and histopathological lesions. The results indicate that LL suppressed HFD-induced obesity, hyperlipidemia, hypercholesterolemia, and hepatic steatosis, suggesting that LL might be a promising adjuvant therapy for treatment of these metabolic disorders related to corpulence.